These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

57 related items for PubMed ID: 108388

  • 1. Rhodotorulic acid--investigation of its potential as an iron-chelating drug.
    Grady RW, Peterson CM, Jones RL, Graziano JH, Bhargava KK, Berdoukas VA, Kokkini G, Loukopoulos D, Cerami A.
    J Pharmacol Exp Ther; 1979 Jun; 209(3):342-8. PubMed ID: 108388
    [Abstract] [Full Text] [Related]

  • 2. The development of new iron-chelating drugs.
    Grady RW, Graziano JH, Akers HA, Cerami A.
    J Pharmacol Exp Ther; 1976 Feb; 196(2):478-85. PubMed ID: 1255491
    [Abstract] [Full Text] [Related]

  • 3. The development of new iron-chelating drugs. II.
    Grady RW, Graziano JH, White GP, Jacobs A, Cerami A.
    J Pharmacol Exp Ther; 1978 Jun; 205(3):575-65. PubMed ID: 660531
    [Abstract] [Full Text] [Related]

  • 4. Coordination chemistry of microbial iron transport compounds: rhodotorulic acid and iron uptake in Rhodotorula pilimanae.
    Carrano CJ, Raymond KN.
    J Bacteriol; 1978 Oct; 136(1):69-74. PubMed ID: 30750
    [Abstract] [Full Text] [Related]

  • 5. The selection and evaluation of new chelating agents for the treatment of iron overload.
    Pitt CG, Gupta G, Estes WE, Rosenkrantz H, Metterville JJ, Crumbliss AL, Palmer RA, Nordquest KW, Hardy KA, Whitcomb DR, Byers BR, Arceneaux JE, Gaines CG, Sciortino CV.
    J Pharmacol Exp Ther; 1979 Jan; 208(1):12-8. PubMed ID: 759605
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of iron-chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron-chelating drug.
    Hershko C, Grady RW, Link G.
    Br J Haematol; 1982 Jun; 51(2):251-60. PubMed ID: 7082583
    [Abstract] [Full Text] [Related]

  • 7. Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients.
    De Virgiliis S, Cossu P, Toccafondi C, Sanna G, Frau F, Lobrano R, Cornacchia G, Nucaro A, Loi A, Bertolino F, Cao A.
    Am J Pediatr Hematol Oncol; 1983 Jun; 5(1):73-7. PubMed ID: 6859457
    [Abstract] [Full Text] [Related]

  • 8. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA, Taqi A, Deghaidi A.
    Pediatr Hematol Oncol; 2004 Jun; 21(5):453-60. PubMed ID: 15205089
    [Abstract] [Full Text] [Related]

  • 9. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.
    Hershko C, Avramovici-Grisaru S, Link G, Gelfand L, Sarel S.
    J Lab Clin Med; 1981 Jul; 98(1):99-108. PubMed ID: 7252329
    [Abstract] [Full Text] [Related]

  • 10. Effect of desferrioxamine, rhodotorulic acid and cholylhydroxamic acid on transferrin and iron exchange with hepatocytes in culture.
    Baker E, Page M, Torrance J, Grady R.
    Clin Physiol Biochem; 1985 Jul; 3(6):277-88. PubMed ID: 4075694
    [Abstract] [Full Text] [Related]

  • 11. N-phthaloyl-glycine-hydroxamic acid as serum iron chelator in rats.
    Matijević-Sosa J, Samarzija I, Honović L, Jurisić B.
    Acta Pharm; 2008 Jun; 58(2):231-6. PubMed ID: 18515233
    [Abstract] [Full Text] [Related]

  • 12. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P, Grady RW, Dragsten P, Vichinsky E, Giardina P, Madden J, Jeng M, Miller B, Hanson G, Hedlund B.
    Br J Haematol; 2007 Aug; 138(3):374-81. PubMed ID: 17614825
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of polymeric hydroxamic acid iron chelators for treatment of iron overload.
    Winston A, Varaprasad DV, Metterville JJ, Rosenkrantz H.
    J Pharmacol Exp Ther; 1985 Mar; 232(3):644-9. PubMed ID: 3973822
    [Abstract] [Full Text] [Related]

  • 14. Development and evaluation of the improved iron chelating agents EHPG, HBED and their dimethyl esters.
    Hershko C, Grady RW, Link G.
    Haematologia (Budap); 1984 Mar; 17(1):25-33. PubMed ID: 6427069
    [Abstract] [Full Text] [Related]

  • 15. Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization.
    Hershko C, Grady RW, Cerami A.
    J Lab Clin Med; 1978 Aug; 92(2):144-51. PubMed ID: 681807
    [Abstract] [Full Text] [Related]

  • 16. Prooxidant activity of ferrioxamine in isolated rat hepatocytes and linoleic acid micelles.
    Bergamini S, Rota C, Staffieri M, Tomasi A, Iannone A.
    Chem Res Toxicol; 1999 Apr; 12(4):365-70. PubMed ID: 10207126
    [Abstract] [Full Text] [Related]

  • 17. Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetic acid (HBED). Comparison with desferrioxamine.
    Lau EH, Cerny EA, Wright BJ, Rahman YE.
    J Lab Clin Med; 1983 May; 101(5):806-16. PubMed ID: 6403640
    [Abstract] [Full Text] [Related]

  • 18. The identification of 2, 3-dihydroxybenzoic acid as a potentially useful iron-chelating drug.
    Graziano JH, Grady RW, Cerami A.
    J Pharmacol Exp Ther; 1974 Sep; 190(3):570-5. PubMed ID: 4416298
    [No Abstract] [Full Text] [Related]

  • 19. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.
    Donovan JM, Plone M, Dagher R, Bree M, Marquis J.
    Ann N Y Acad Sci; 2005 Sep; 1054():492-4. PubMed ID: 16339704
    [Abstract] [Full Text] [Related]

  • 20. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR, Mahony BS, Githens JH, Rhoades ED.
    Am J Pediatr Hematol Oncol; 1982 Sep; 4(2):115-23. PubMed ID: 7114394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.